Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bluebird Bio (BLUE)

Bluebird Bio (BLUE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,713,854
  • Shares Outstanding, K 67,448
  • Annual Sales, $ 250,730 K
  • Annual Income, $ -618,700 K
  • 60-Month Beta 1.75
  • Price/Sales 6.90
  • Price/Cash Flow N/A
  • Price/Book 1.44
Trade BLUE with:

Options Overview

Details
  • Implied Volatility 66.22%
  • Historical Volatility 26.00%
  • IV Percentile 46%
  • IV Rank 18.82%
  • IV High 124.24% on 03/26/21
  • IV Low 52.77% on 01/21/21
  • Put/Call Vol Ratio 2.47
  • Today's Volume 461
  • Volume Avg (30-Day) 801
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 30,635
  • Open Int (30-Day) 32,311

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -3.26
  • Number of Estimates 11
  • High Estimate -3.02
  • Low Estimate -3.84
  • Prior Year -0.36
  • Growth Rate Est. (year over year) -805.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.20 +1.59%
on 08/02/21
31.75 -19.37%
on 07/06/21
-5.77 (-18.39%)
since 07/02/21
3-Month
25.20 +1.59%
on 08/02/21
35.59 -28.07%
on 06/14/21
-4.40 (-14.67%)
since 04/30/21
52-Week
24.24 +5.61%
on 02/23/21
68.39 -62.57%
on 08/06/20
-35.10 (-57.83%)
since 07/31/20

Most Recent Stories

More News
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies

--Alliance designed to foster best in class cell therapy product and manufacturing innovation through risk-sharing and royalty-based model

BLUE : 25.60 (+0.75%)
Bristol Myers Squibb Reports Second Quarter Financial Results for 2021

Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2021, which reflect robust product sales, continued advancement of the pipeline and strong clinical and operational performance...

BMY : 68.02 (+0.22%)
XLRN : 124.72 (-0.27%)
BLUE : 25.60 (+0.75%)
AGEN : 5.29 (+2.12%)
Is a Beat in Store for Bristol-Myers (BMY) in Q2 Earnings?

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2021 results.

IRWD : 13.27 (unch)
BMY : 68.02 (+0.22%)
PFE : 43.96 (+2.69%)
BLUE : 25.60 (+0.75%)
BLUEBIRD BIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE

/PRNewswire/ -- Former Attorney General of , , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into bluebird bio, Inc. (NasdaqGS: BLUE).  ...

BLUE : 25.60 (+0.75%)
bluebird bio Receives EC Approval for SKYSONA(TM) (elivaldogene autotemcel, Lenti-D(TM)) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched Sibling Donor

--CALD is a rare neurodegenerative disease that can lead to progressive, irreversible loss of neurologic function, and death

BLUE : 25.60 (+0.75%)
Bristol-Myers (BMY) Gains 7.6% YTD: What to Expect in 2H

Bristol-Myers (BMY) maintains momentum on new drug approvals despite some key established drugs facing challenges.

BMY : 68.02 (+0.22%)
PFE : 43.96 (+2.69%)
RGEN : 247.87 (+0.88%)
BLUE : 25.60 (+0.75%)
bluebird bio Announces Positive Recommendation by PRAC Regarding Article 20 Safety Referral Review of ZYNTEGLO(TM) Gene Therapy for Transfusion-Dependent B-thalassemia and Marketing to Resume in EU

--Company has informed EMA of lift of voluntary temporary marketing suspension

BLUE : 25.60 (+0.75%)
Bristol Myers (BMY) Gets Positive CHMP Opinion for Abecma

Bristol Myers (BMY) obtains positive CHMP opinion for cell immunotherapy, Abecma, for multiple myeloma and Opdivo for the indication of gastroesophageal junction cancer.

BMY : 68.02 (+0.22%)
MRK : 76.18 (-0.90%)
RGEN : 247.87 (+0.88%)
BLUE : 25.60 (+0.75%)
Bristol Myers' (BMY) Onureg Gets European Commission Approval

Bristol Myers (BMY) wins approval for acute myeloid leukemia drug, Onureg, in the European Union.

BMY : 68.02 (+0.22%)
MRK : 76.18 (-0.90%)
RGEN : 247.87 (+0.88%)
BLUE : 25.60 (+0.75%)
Bristol-Myers (BMY) Partners Eisai for Antibody Drug Conjugate

Bristol-Myers (BMY) teams up with Eisai to co develop MORAb-202, an antibody drug conjugate (ADC).

BMY : 68.02 (+0.22%)
MRK : 76.18 (-0.90%)
RGEN : 247.87 (+0.88%)
BLUE : 25.60 (+0.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio,...

See More

Key Turning Points

3rd Resistance Point 26.50
2nd Resistance Point 26.16
1st Resistance Point 25.88
Last Price 25.60
1st Support Level 25.26
2nd Support Level 24.92
3rd Support Level 24.64

See More

52-Week High 68.39
Fibonacci 61.8% 51.52
Fibonacci 50% 46.31
Fibonacci 38.2% 41.11
Last Price 25.60
52-Week Low 24.24

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar